4//SEC Filing
TIDWELL ROBERT H 4
Accession 0001235802-09-000111
CIK 0000865231other
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 5:22 PM ET
Size
37.9 KB
Accession
0001235802-09-000111
Insider Transaction Report
Form 4
CELL GENESYS INCcege
TIDWELL ROBERT H
SVP Corp. Development
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−20,039→ 0 totalExercise: $6.07Exp: 2016-02-07→ common stock (20,039 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−30,000→ 0 totalExercise: $9.14Exp: 2013-02-04→ common stock (30,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−27,747→ 0 totalExercise: $1.84Exp: 2018-02-06→ common stock (27,747 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−40,000→ 0 totalExercise: $14.04Exp: 2014-02-02→ common stock (40,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−23,958→ 0 totalExercise: $3.07Exp: 2017-02-07→ common stock (23,958 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−37,253→ 0 totalExercise: $1.84Exp: 2018-02-06→ common stock (37,253 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−13,123→ 0 totalExercise: $6.73Exp: 2015-02-03→ common stock (13.123 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−50,000→ 0 totalExercise: $11.95Exp: 2012-07-24→ common stock (50,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−10,000→ 0 totalExercise: $19.63Exp: 2011-02-06→ common stock (10,000 underlying) - Disposition to Issuer
Common Stock
2009-10-14−15,949→ 0 total - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−26,042→ 0 totalExercise: $3.07Exp: 2017-02-07→ common stock (26,042 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−9,961→ 0 totalExercise: $6.07Exp: 2016-02-07→ common stock (9,961 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−41,877→ 0 totalExercise: $6.73Exp: 2015-02-03→ common stock (41,877 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−22,500→ 0 totalExercise: $15.42Exp: 2012-02-07→ common stock (22,500 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−100,000→ 0 totalExercise: $30.81Exp: 2010-08-31→ common stock (100,000 underlying)
Footnotes (15)
- [F1]Pursuant to the merger of Cell Genesys, Inc. with and into BioSante Pharmaceuticals, Inc. (the "Merger"), such shares were disposed of in exchange for 2,915 shares of BioSante common stock having a market value of $1.82 per share on the effective date of the Merger.
- [F10]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 1,820 shares of BioSante common stock for an exercise price of $33.21 per share.
- [F11]Options granted on February 3, 2005. Vesting occurs over a period of four years in a series of forty-eight (48) successive, equal monthly installments beginning on the grant date.
- [F12]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 7,655 shares of BioSante common stock for an exercise price of $36.82 per share.
- [F13]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 2,398 shares of BioSante common stock for an exercise price of $36.82 per share.
- [F14]This option is fully vested.
- [F15]This option was terminated for no consideration upon the effective time of the Merger.
- [F2]Options granted on February 6, 2008. Vesting occurs over a period of four years in a series of forty-eight (48) successive, equal monthly installments beginning on the grant date.
- [F3]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 5,072 shares of BioSante common stock for an exercise price of $10.07 per share.
- [F4]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 6,809 shares of BioSante common stock for an exercise price of $10.07 per share.
- [F5]Options granted on February 7, 2007. Vesting occurs over a period of four years in a series of forty-eight (48) successive, equal monthly installments beginning on the grant date.
- [F6]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 4,760 shares of BioSante common stock for an exercise price of $16.80 per share.
- [F7]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 4,379 shares of BioSante common stock for an exercise price of $16.80 per share.
- [F8]Options granted on February 7, 2006. Vesting occurs over a period of four years in a series of forty-eight (48) successive, equal monthly installments beginning on the grant date.
- [F9]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 3,663 shares of BioSante common stock for an exercise price of $33.21 per share.
Documents
Issuer
CELL GENESYS INC
CIK 0000865231
Entity typeother
Related Parties
1- filerCIK 0001202441
Filing Metadata
- Form type
- 4
- Filed
- Oct 14, 8:00 PM ET
- Accepted
- Oct 15, 5:22 PM ET
- Size
- 37.9 KB